<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><meta name="description" content='Primary sclerosing cholangitis is an autoimmune disease leading to
  destruction of the small bile ducts in the liver.  Progression is
  slow but inexhortable, eventually leading to cirrhosis and liver
  decompensation.
  The condition has been recognised since at least 1851 and was named
  "primary biliary cirrhosis" in 1949.
  Because cirrhosis is a feature only of advanced disease, a change of
  its name to "primary biliary cholangitis" was proposed by patient
  advocacy groups in 2014.  
This data is from the Mayo Clinic trial in PBC conducted between 1974
and 1984.  
A total of 424 PBC patients, referred to Mayo Clinic during that ten-year
interval, met eligibility criteria for the randomized placebo controlled
trial of the drug D-penicillamine.  The first 312 cases in the data set
participated in the randomized trial and contain largely complete data.  The
additional 112 cases did not participate in the clinical trial, but consented
to have basic measurements recorded and to be followed for survival.  Six of
those cases were lost to follow-up shortly after diagnosis, so the data here
are on an additional 106 cases as well as the 312 randomized participants.    
A nearly identical data set found in appendix D of Fleming and Harrington;
this version has fewer missing values.'><title>Mayo Clinic Primary Biliary Cholangitis Data — pbc • survival</title><!-- favicons --><link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png"><link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png"><link rel="apple-touch-icon" type="image/png" sizes="180x180" href="../apple-touch-icon.png"><link rel="apple-touch-icon" type="image/png" sizes="120x120" href="../apple-touch-icon-120x120.png"><link rel="apple-touch-icon" type="image/png" sizes="76x76" href="../apple-touch-icon-76x76.png"><link rel="apple-touch-icon" type="image/png" sizes="60x60" href="../apple-touch-icon-60x60.png"><script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><link href="../deps/bootstrap-5.3.1/bootstrap.min.css" rel="stylesheet"><script src="../deps/bootstrap-5.3.1/bootstrap.bundle.min.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous"><!-- bootstrap-toc --><script src="https://cdn.jsdelivr.net/gh/afeld/bootstrap-toc@v1.0.1/dist/bootstrap-toc.min.js" integrity="sha256-4veVQbu7//Lk5TSmc7YV48MxtMy98e26cf5MrgZYnwo=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- search --><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Mayo Clinic Primary Biliary Cholangitis Data — pbc"><meta property="og:description" content='Primary sclerosing cholangitis is an autoimmune disease leading to
  destruction of the small bile ducts in the liver.  Progression is
  slow but inexhortable, eventually leading to cirrhosis and liver
  decompensation.
  The condition has been recognised since at least 1851 and was named
  "primary biliary cirrhosis" in 1949.
  Because cirrhosis is a feature only of advanced disease, a change of
  its name to "primary biliary cholangitis" was proposed by patient
  advocacy groups in 2014.  
This data is from the Mayo Clinic trial in PBC conducted between 1974
and 1984.  
A total of 424 PBC patients, referred to Mayo Clinic during that ten-year
interval, met eligibility criteria for the randomized placebo controlled
trial of the drug D-penicillamine.  The first 312 cases in the data set
participated in the randomized trial and contain largely complete data.  The
additional 112 cases did not participate in the clinical trial, but consented
to have basic measurements recorded and to be followed for survival.  Six of
those cases were lost to follow-up shortly after diagnosis, so the data here
are on an additional 106 cases as well as the 312 randomized participants.    
A nearly identical data set found in appendix D of Fleming and Harrington;
this version has fewer missing values.'><meta property="og:image" content="/logo.png"><!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]--></head><body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>
    

    <nav class="navbar fixed-top navbar-light navbar-expand-lg bg-light"><div class="container">
    
    <a class="navbar-brand me-2" href="../index.html">survival</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">3.5-6</small>

    
    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto"><li class="active nav-item">
  <a class="nav-link" href="../reference/index.html">Reference</a>
</li>
<li class="nav-item dropdown">
  <a href="#" class="nav-link dropdown-toggle" data-bs-toggle="dropdown" role="button" aria-expanded="false" aria-haspopup="true" id="dropdown-articles">Articles</a>
  <div class="dropdown-menu" aria-labelledby="dropdown-articles">
    <a class="dropdown-item" href="../articles/example-analysis.html">Example Analysis</a>
  </div>
</li>
      </ul><form class="form-inline my-2 my-lg-0" role="search">
        <input type="search" class="form-control me-sm-2" aria-label="Toggle navigation" name="search-input" data-search-index="../search.json" id="search-input" placeholder="Search for" autocomplete="off"></form>

      <ul class="navbar-nav"><li class="nav-item">
  <a class="external-link nav-link" href="https://github.com/therneau/survival/" aria-label="github">
    <span class="fab fa fab fa-github fa-lg"></span>
     
  </a>
</li>
      </ul></div>

    
  </div>
</nav><div class="container template-reference-topic">
<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">
      <img src="../logo.png" class="logo" alt=""><h1>Mayo Clinic Primary Biliary Cholangitis Data</h1>
      
      <div class="d-none name"><code>pbc.Rd</code></div>
    </div>

    <div class="ref-description section level2">
    <p>Primary sclerosing cholangitis is an autoimmune disease leading to
  destruction of the small bile ducts in the liver.  Progression is
  slow but inexhortable, eventually leading to cirrhosis and liver
  decompensation.
  The condition has been recognised since at least 1851 and was named
  "primary biliary cirrhosis" in 1949.
  Because cirrhosis is a feature only of advanced disease, a change of
  its name to "primary biliary cholangitis" was proposed by patient
  advocacy groups in 2014.</p>  
<p>This data is from the Mayo Clinic trial in PBC conducted between 1974
and 1984.  
A total of 424 PBC patients, referred to Mayo Clinic during that ten-year
interval, met eligibility criteria for the randomized placebo controlled
trial of the drug D-penicillamine.  The first 312 cases in the data set
participated in the randomized trial and contain largely complete data.  The
additional 112 cases did not participate in the clinical trial, but consented
to have basic measurements recorded and to be followed for survival.  Six of
those cases were lost to follow-up shortly after diagnosis, so the data here
are on an additional 106 cases as well as the 312 randomized participants.</p>    
<p>A nearly identical data set found in appendix D of Fleming and Harrington;
this version has fewer missing values.</p>
    </div>

    <div class="section level2">
    <h2 id="ref-usage">Usage<a class="anchor" aria-label="anchor" href="#ref-usage"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span><span class="va">pbc</span></span>
<span><span class="fu"><a href="https://rdrr.io/r/utils/data.html" class="external-link">data</a></span><span class="op">(</span><span class="va">pbc</span>, package<span class="op">=</span><span class="st">"survival"</span><span class="op">)</span></span></code></pre></div>
    </div>

    <div class="section level2">
    <h2 id="format">Format<a class="anchor" aria-label="anchor" href="#format"></a></h2>
    <p></p><table class="table table"><tr><td>age:</td><td>in years</td></tr><tr><td>albumin:</td><td>serum albumin (g/dl)</td></tr><tr><td>alk.phos:</td><td>alkaline phosphotase (U/liter)</td></tr><tr><td>ascites:</td><td>presence of ascites</td></tr><tr><td>ast:</td><td>aspartate aminotransferase, once called SGOT (U/ml)</td></tr><tr><td>bili:</td><td>serum bilirunbin (mg/dl)</td></tr><tr><td>chol:</td><td>serum cholesterol (mg/dl)</td></tr><tr><td>copper:</td><td>urine copper (ug/day)</td></tr><tr><td>edema:</td><td>0 no edema, 0.5 untreated or successfully treated</td></tr><tr><td></td><td>1 edema despite diuretic therapy</td></tr><tr><td>hepato:</td><td>presence of hepatomegaly or enlarged liver</td></tr><tr><td>id:</td><td>case number</td></tr><tr><td>platelet:</td><td>platelet count</td></tr><tr><td>protime:</td><td>standardised blood clotting time</td></tr><tr><td>sex:</td><td>m/f</td></tr><tr><td>spiders:</td><td>blood vessel malformations in the skin</td></tr><tr><td>stage:</td><td>histologic stage of disease (needs biopsy)</td></tr><tr><td>status:</td><td>status at endpoint, 0/1/2 for censored, transplant, dead</td></tr><tr><td>time:</td><td>number of days between registration and the earlier of death,</td></tr><tr><td></td><td>transplantion, or study analysis in July, 1986</td></tr><tr><td>trt:</td><td>1/2/NA for D-penicillmain, placebo, not randomised</td></tr><tr><td>trig:</td><td>triglycerides (mg/dl)</td></tr></table></div>
    <div class="section level2">
    <h2 id="source">Source<a class="anchor" aria-label="anchor" href="#source"></a></h2>
    <p>T Therneau and P Grambsch (2000),
  <em>Modeling Survival Data: Extending the Cox Model</em>,
  Springer-Verlag, New York.
  ISBN: 0-387-98784-3.</p>
    </div>
    <div class="section level2">
    <h2 id="see-also">See also<a class="anchor" aria-label="anchor" href="#see-also"></a></h2>
    <div class="dont-index"><p><code><a href="pbcseq.html">pbcseq</a></code></p></div>
    </div>

  </main><aside class="col-md-3"><nav id="toc"><h2>On this page</h2>
    </nav></aside></div>


    <footer><div class="pkgdown-footer-left">
  <p></p><p>Developed by Terry M Therneau.</p>
</div>

<div class="pkgdown-footer-right">
  <p></p><p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.0.7.</p>
</div>

    </footer></div>

  

  

  </body></html>

